اخبار و اعلانات

 آمار

تعداد نشریات283
تعداد نشریات سازمان81
تعداد شماره‌ها2,726
تعداد مقالات31,042
تعداد مشاهده مقاله28,105,972
تعداد دریافت فایل اصل مقاله16,248,263
Modher Nabat Al-Ajrash, A, Mohammed Ali, S. H, Al-Bayaa, Y. J, MohammedAl-Alwany, S. H, Al-Hijazi, A. Y. (1401). Assessment of Interleukin-13(rs20541) Genomic Polymorphism in Patients with Acute Respiratory Distress Syndrome in Relation to COVID19 Infection. سامانه مدیریت نشریات علمی, 77(6), 2291-2298. doi: 10.22092/ari.2022.358616.2266
A Modher Nabat Al-Ajrash; S. H Mohammed Ali; Y. J Al-Bayaa; S. H MohammedAl-Alwany; A. Y Al-Hijazi. "Assessment of Interleukin-13(rs20541) Genomic Polymorphism in Patients with Acute Respiratory Distress Syndrome in Relation to COVID19 Infection". سامانه مدیریت نشریات علمی, 77, 6, 1401, 2291-2298. doi: 10.22092/ari.2022.358616.2266
Modher Nabat Al-Ajrash, A, Mohammed Ali, S. H, Al-Bayaa, Y. J, MohammedAl-Alwany, S. H, Al-Hijazi, A. Y. (1401). 'Assessment of Interleukin-13(rs20541) Genomic Polymorphism in Patients with Acute Respiratory Distress Syndrome in Relation to COVID19 Infection', سامانه مدیریت نشریات علمی, 77(6), pp. 2291-2298. doi: 10.22092/ari.2022.358616.2266
Modher Nabat Al-Ajrash, A, Mohammed Ali, S. H, Al-Bayaa, Y. J, MohammedAl-Alwany, S. H, Al-Hijazi, A. Y. Assessment of Interleukin-13(rs20541) Genomic Polymorphism in Patients with Acute Respiratory Distress Syndrome in Relation to COVID19 Infection. سامانه مدیریت نشریات علمی, 1401; 77(6): 2291-2298. doi: 10.22092/ari.2022.358616.2266

Assessment of Interleukin-13(rs20541) Genomic Polymorphism in Patients with Acute Respiratory Distress Syndrome in Relation to COVID19 Infection

Archives of Razi Institute
مقاله 34، دوره 77، شماره 6، بهمن و اسفند 2022، صفحه 2291-2298    اصل مقاله (594.8 K)
نوع مقاله: Original Articles
شناسه دیجیتال (DOI): 10.22092/ari.2022.358616.2266
نویسندگان
A Modher Nabat Al-Ajrash1؛ S. H Mohammed Ali2؛ Y. J Al-Bayaa2؛ S. H MohammedAl-Alwany* 3؛ A. Y Al-Hijazi4
1Ministry of Health, Imam Sadiq Teaching Hospital, Hillah, Iraq
2College of Medicine, University of Baghdad, Baghdad, Iraq
3College of Science, University of Babylon, Babylon, Iraq
4Al-Mustaqbal University College, Dentistry Department, Babylon, Iraq
چکیده
Elevated Interleukin-13 (IL-13) may play an important role in the pathophysiology of COVID-19, yet, the attenuated response did not notice across all severe cases. Susceptibility to asthma in specific populations is associated with several SNPs of multifunctional cytokines, such as IL-13, IL-31 and IL-33. This prospective case-control study is designed to investigate the extent of genetic susceptibility in subsets of Iraqi patients with COVID-19 by targeting the variants of interleukin IL-13rs20541 polymorphism in relation to disease susceptibility and severity of clinical presentation. One hundred samples were obtained from the throat, nasopharyngeal and nasal swabs enrolled in this study. Eighty samples of the throat, nasopharyngeal and nasal localization swabs were obtained from patients with acute respiratory distress syndrome (ARDS) (both COVID-19 and non-COVID19 patients), while other 20 nasopharyngeal swabs were included as a healthy control group (AHC). Detection of IL-13rs20541 polymorphism was done by ARMS technique. The frequencies of GG- genotype in ARDS- patients with COVID-19, non-COVID19-, and AHC groups were respectively 14%, 12% and 3%, where, and as compared to the control group, showed a significant increase in COVID-19 patients. The AA- genotype in patients with COVID-19 group, non- COVID-19 group and healthy control group documented the frequency of 9%, 7%, and 14%, respectively, where the frequency decreased in the patient's groups as compared to the AHC group. Finally, and among the studied groups, an increase of AG- genotype (as rate OR=1.89) was documented compared to genotype GG and A-. Genetic polymorphisms in the IL-13rs20541 gene might influence its functions in patients with SARS-associated respiratory tract infection and thus might involve the pathogenicity of patients with COVID-19.
کلیدواژه‌ها
Interleukin-13؛ Genomic Polymorphism؛ Distress Syndrome
سایر فایل های مرتبط با مقاله
مراجع
  1. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-80.
  2. Mangalmurti N, Hunter CA. Cytokine storms: understanding COVID-19. Immunity. 2020;53(1):19-25.
  3. Group T. The RECOVERY Collaborative Group Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384:693-704.
  4. Mannon P, Reinisch W. Interleukin 13 and its role in gut defence and inflammation. Gut. 2012;61(12):1765-73.
  5. Wynn TA. IL-13 effector functions. Annual review of immunology. 2003;21(1):425-56.
  6. Ontong P, Prachayasittikul V. Unraveled roles of hyaluronan in severe COVID-19. EXCLI J. 2021;20:117.
  7. Le Floc’h A, Allinne J, Nagashima K, Scott G, Birchard D, Asrat S, et al. Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation. Allergy. 2020;75(5):1188-204.
  8. Vaz de Paula CB, de Azevedo MLV, Nagashima S, Martins APC, Malaquias MAS, Miggiolaro AFRdS, et al. IL-4/IL-13 remodeling pathway of COVID-19 lung injury. Sci Rep. 2020;10(1):1-8.
  9. Meftahi GH, Jangravi Z, Sahraei H, Bahari Z. The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of “inflame-aging”. J Inflamm Res. 2020;69(9):825-39.
  10. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-4.
  11. Donlan AN, Sutherland TE, Marie C, Preissner S, Bradley BT, Carpenter RM, et al. IL-13 is a driver of COVID-19 severity. JCI Insight. 2021;6(15).
  12. Patruno C, Stingeni L, Fabbrocini G, Hansel K, Napolitano M. Dupilumab and COVID‐19: what should we expect? Dermatol Ther. 2020;33(4):13502.
  13. León B, Ballesteros-Tato A. Modulating Th2 cell immunity for the treatment of asthma. Front Immunol. 2021;12:268.
  14. Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021;384(9):795-807.
  15. Rathnasinghe R, Strohmeier S, Amanat F, Gillespie VL, Krammer F, García-Sastre A, et al. Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection. Emerg Microbes Infect. 2020;9(1):2433-45.
  16. Lucas C, Wong P, Klein J, Castro TB, Silva J, Sundaram M, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature. 2020;584(7821):463-9.
  17. Saini KS, Tagliamento M, Lambertini M, McNally R, Romano M, Leone M, et al. Mortality in patients with cancer and coronavirus disease 2019: a systematic review and pooled analysis of 52 studies. Eur J Cancer. 2020;139:43-50.
  18. Ahuja A, Samudra M, Prasad SP, Chaudhury S, Bora S, Singh V, et al. Correlates of depression, anxiety, self-esteem, and suicidal ideas in COVID-associated mucormycosis patients and the effects of treatment. Ind Psychiatry J. 2021;30(Suppl 1):S75.
  19. Akbar AN, Gilroy DW. Aging immunity may exacerbate COVID-19. Science. 2020;369(6501):256-7.
  20. Jacobs I, Ceulemans M, Wauters L, Breynaert C, Vermeire S, Verstockt B, et al. Role of Eosinophils in Intestinal Inflammation and Fibrosis in Inflammatory Bowel Disease: An Overlooked Villain? Front Immunol. 2021:4355.
  21. Passalacqua G, Mincarini M, Colombo D, Troisi G, Ferrari M, Bagnasco D, et al. IL-13 and idiopathic pulmonary fibrosis: Possible links and new therapeutic strategies. Pulm Pharmacol Ther. 2017;45:95-100.
  22. Song J, Zeng M, Wang H, Qin C, Hou HY, Sun ZY, et al. Distinct effects of asthma and COPD comorbidity on disease expression and outcome in patients with COVID‐19. Allergy. 2021;76(2):483-96.
  23. Du H, Dong X, Zhang Jj, Cao Yy, Akdis M, Huang Pq, et al. Clinical characteristics of 182 pediatric COVID‐19 patients with different severities and allergic status. Allergy. 2021;76(2):510-32.
  24. Yang B, Chang X, Huang J, Pan W, Si Z, Zhang C, et al. The role of IL-6/lymphocyte ratio in the peripheral blood of severe patients with COVID-19. Int Immunopharmacol. 2021;97:107569.
  25. Cunha LL, Perazzio SF, Azzi J, Cravedi P, Riella LV. Remodeling of the immune response with aging: immunosenescence and its potential impact on COVID-19 immune response. Front immunol. 2020:1748.
  26. Zhou B, Thao TTN, Hoffmann D, Taddeo A, Ebert N, Labroussaa F, et al. SARS-CoV-2 spike D614G change enhances replication and transmission. Nature. 2021;592(7852):122-7.
  27. Volz E, Hill V, McCrone JT, Price A, Jorgensen D, O’Toole Á, et al. Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity. Cell. 2021;184(1):64-75.
  1. Fujisawa T, Joshi B, Nakajima A, Puri RK. A novel role of interleukin-13 receptor α2 in pancreatic cancer invasion and metastasis. Cancer Res. 2009;69(22):8678-85.
29.          Murata T, Obiri NI, Debinski W, Puri RK. Structure of IL-13 receptor: analysis of subunit composition in cancer and immune cells. Biochem Biophys Res Commun. 1997;238(1):90-4. 

آمار
تعداد مشاهده مقاله: 5,497
تعداد دریافت فایل اصل مقاله: 338


counter
سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب